This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dewey A. Nelson, MD
48 Omega Dr Omega Professional Center Newark, DE 19713

Arch Neurol. 1989;46(7):718-719.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Between 1960 and 1962, six studies performed on more than 5000 patients reported sanguine results from the intrathecal use of methylprednisolone acetate (Depo-Medrol).¹ Numerous regimens were tried. Sehgal and Gardner² advocated it after treating 3000 patients for "failed disk syndrome," arachnoiditis, cluster headache, pseudotumor cerebri, plexitis, Guillain-Barré syndrome, and multiple sclerosis. Only minor side effects were mentioned and the steroid was reported uniformly helpful. These authors mentioned six negative autopsy reports in a two-sentence description, and no details were given. Boines³ simultaneously tested the compound on more than 2000 patients with multiple sclerosis and reported improvement from 75% to 90%, regardless of the stage of the disease; spasticity was stated to have been relieved, even in patients with chronic disease.

Between 1964 and 1969, three authors^4-6 attempted to treat spasticity in multiple sclerosis and other diseases by a variety of regimens, and their results were poor. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?